Hydroxyurea is active in vitro against multidrug-resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
Conference reports
ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients
16 July 2000. Related: Conference reports, Drug resistance.
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
16 July 2000. Related: Conference reports, Antiretrovirals.
Ritonavir/saquinavir combination: effect of ritonavir dosage
16 July 2000. Related: Conference reports, Antiretrovirals.
What is the significance of blips in viral load?
16 July 2000. Related: Conference reports, Treatment strategies.
Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001
16 July 2000. Related: Conference reports, Drug resistance.
A prospective study of strategic treatment interruptions in patients with chronic HIV-infection
16 July 2000. Related: Conference reports.
Added value of hydroxyurea or IL-2 to STIs remains uncertain
16 July 2000. Related: Conference reports.
Continued benefits from protease inhibitor based therapy despite virological failure
16 July 2000. Related: Conference reports, Drug resistance.
Do resistance mutations disappear off therapy?
16 July 2000. Related: Conference reports, Drug resistance.
Selection of PI mutations during slow decay of VL and resistance after PI failure
16 July 2000. Related: Conference reports, Drug resistance.
Thymidine analogues mutations (TAMS) and other NA-related resistance mutations
16 July 2000. Related: Conference reports, Drug resistance.
Nevirapine vs efavirenz: the SENC trial
16 July 2000. Related: Conference reports, Antiretrovirals.
A warning on simplification strategies: not suitable for all
16 July 2000. Related: Conference reports.
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
16 June 2000. Related: Conference reports.
Exercise testing in HIV patients with random increased lactic acid levels: evidence for a reduced anaerobic threshold with a pattern of mitochondrial dysfunction
15 June 2000. Related: Conference reports, Side effects.
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
15 May 2000. Related: Conference reports.
Clinical studies of indinavir/ritonavir as salvage therapy
15 May 2000. Related: Conference reports, Drug resistance.
Indinavir plus ritonavir: might exposure to higher levels of indinavir overcome protease resistant HIV and prove useful to ‘rescue’ previously failed protease inhibitor based combinations?
15 May 2000. Related: Conference reports, Drug resistance.
First International Workshop in Clinical Pharmacology in HIV Therapy, 30-31 March 2000, Noordwijk, Netherlands
15 May 2000. Related: Conference reports.
TDM: standardisation and quality control
15 May 2000. Related: Conference reports.
TDM in clinical practice
15 May 2000. Related: Conference reports.
ATHENA – Early results from first randomised study of clinical benefits of TDM
15 May 2000. Related: Conference reports.
TDM for individualising dosing – practicality and efficacy for PIs and RTIs
15 May 2000. Related: Conference reports.
TDM and adherence
15 May 2000. Related: Conference reports.
Drug interactions: amprenavir, saquinavir, ABT-378/r (lopinavir/r), indinavir, efavirenz, ritonavir
15 May 2000. Related: Conference reports, PK and drug interactions.
L-Acetyl Carnitine (LAC) improves symptoms of peripheral neuropathy (PN): evidence for increases in cutaneous innervation
15 May 2000. Related: Conference reports, Side effects.
7th Conference on Retroviruses and Opportunistic Infections (ROI), January 30-February 2 2000, San Francisco
14 April 2000. Related: Conference reports.
Paediatrics: children are not small (or miniature) adults
14 April 2000. Related: Conference reports, Paediatric care.
HIV-positive women, pregnancy and newborns
14 April 2000. Related: Conference reports, Pregnancy, Drug resistance.
Flu-like symptoms of severe acute HIV infection develop after suspension of HAART
14 April 2000. Related: Conference reports.
Non-clade B virus: epidemiology, testing strategies and resistance
14 April 2000. Related: Conference reports, Drug resistance.